Skip to content

Abbott ABT Other accrued liabilities

Other accrued liabilities at other companies

DexCom logo
DexComDXCM
Edwards Lifesciences logo
Edwards LifesciencesEW
Medline, Inc.
 logo
Medline, Inc. MDLN

Other financials

Income statement

See full
Revenue$11.2B+7.8%
Gross profit$6.3B+6.5%
Operating income$1.3B-20.6%
Net income$1.1B-18.7%
EPS (diluted)$0.61-19.7%

Balance sheet

See full
Cash & equivalents$6.8B+4.2%
Total debt$34.0B+157%
Total equity$52.1B+6.7%
Total assets$110.43B+35.6%

Cash flow

See full
Operating cash flow$1.3B-7.2%
CapEx$399.0M-17.6%
Free cash flow$916.0M-1.8%

Valuation

See full
Market cap$154.15B-22.5%
Enterprise value$181.39B-13.1%
P/E24.6×+9.8×
P/S3.4×-1.3×

Profitability

See full
Gross margin56.3%+0.4pp
Operating margin17.1%+0.2pp
Net margin13.9%-18.0pp

Returns & leverage

See full
Return on equity12.4%-18.4pp
Debt / equity0.7×+0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.

The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Abbott's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Abbott's other accrued liabilities?
Abbott (ABT) reported other accrued liabilities of $6.38B in Q1 2026.
How has Abbott's other accrued liabilities changed year-over-year?
Abbott's other accrued liabilities increased by 13.9% year-over-year, from $5.6B to $6.38B.
What is the long-term trend for Abbott's other accrued liabilities?
Over 5 years (2020 to 2025), Abbott's other accrued liabilities has grown at a 2.4% compound annual growth rate (CAGR), from $5.17B to $5.81B.